Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 2Pancreatic Cancer Non-resectable 1Neoplasms 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 152Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 63Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × pamrevlumab × Gastrointestinal × Clear all
NCT03941093 2024-11-05

LAPIS

Kyntra Bio

Phase 3 Completed
284 enrolled 14 charts
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT02210559 2023-03-02

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Kyntra Bio

Phase 1/2 Completed
37 enrolled 16 charts
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT01181245 2014-08-06

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Kyntra Bio

Phase 1 Completed
50 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡